Mineralys Therapeutics, Inc.
MLYS
$42.16
$2.777.03%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -190.77M | -188.51M | -177.81M | -153.25M | -119.67M |
Total Depreciation and Amortization | 57.00K | 50.00K | 43.00K | 28.00K | 17.00K |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 7.15M | 4.85M | 1.93M | -475.00K | -1.29M |
Change in Net Operating Assets | -9.12M | -9.05M | 9.52M | 25.25M | 23.64M |
Cash from Operations | -192.69M | -192.66M | -166.31M | -128.45M | -97.30M |
Capital Expenditure | -37.00K | -37.00K | -96.00K | -96.00K | -59.00K |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 27.46M | 78.07M | 115.06M | 23.40M | -52.24M |
Cash from Investing | 27.42M | 78.04M | 114.96M | 23.30M | -52.30M |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 199.34M | 189.60M | 116.58M | 116.51M | 116.66M |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -145.00K | -382.00K | -435.00K | -388.00K | -347.00K |
Cash from Financing | 199.20M | 189.22M | 116.14M | 116.13M | 116.31M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 33.93M | 74.59M | 64.79M | 10.97M | -33.28M |